Natalie Yeadon looks at how the industry can help healthcare professionals, patients, and their families combat false and misleading scientific information.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh